Dexamethasone as risk-factor for ICU-acquired respiratory tract infections in severe COVID-19

Article

Abstract: Purpose: Dexamethasone is the only drug that has consistently reduced mortality in patients with COV

Palabras claves:

covid-19, Critical care, Dexamethasone, Pneumonia, Severe COVID-19

Autores:

Albaya-Moreno A., Bastidas A., Bodí M., Díaz A.M., Díaz E., Estella A., Ferrer R., Fuentes Y.V., García-Gallo E., Hernandez G., Jorge-García R., Loza-Vazquez A., Manuel Jibaja, Martín-Loeches I., Moreno G., Ospina-Tascón G.A., Parra-Tanoux D., Reyes L.F., Rodríguez A.H., Sancho I., Silva E., Socías L., Solé-Violán J., Vera-Alarcon M.

Fuentes:

scopus